oxazolidin-2-one has been researched along with 2019 Novel Coronavirus Disease in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, YH; Chen, YS; Cheng, SH; Chien, YC; Hsueh, PR; Ko, WC; Lee, CM; Lee, WS; Lee, YL; Lin, CY; Liu, CP; Liu, PY; Lu, MC; Lu, PL; Shao, PL; Sheng, WH; Shi, ZY; Tseng, SH; Wang, FD; Wang, LS; Wu, TS; Yen, MY | 1 |
1 other study(ies) available for oxazolidin-2-one and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
National surveillance of antimicrobial susceptibilities to dalbavancin, telavancin, tedizolid, eravacycline, omadacycline and other comparator antibiotics and serotype distribution of invasive Streptococcus pneumoniae isolates in adults: results from the
Topics: Adult; Aminoglycosides; Anti-Bacterial Agents; COVID-19; Drug Resistance, Bacterial; Humans; Lipoglycopeptides; Oxazolidinones; Pandemics; SARS-CoV-2; Serogroup; Streptococcus pneumoniae; Taiwan; Teicoplanin; Tetracyclines; Tetrazoles | 2021 |